Control of arthropods in animals

ABSTRACT

A method of controlling parasites in or on an animal comprising administering to the animal a parasiticidally effective, substantially non-emetic 1-arylpyrazole.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application is a divisional of co-pending U.S. patent application Ser. No. 09/727,684, filed Dec. 4, 2000, now allowed, which claims the benefit of U.S. Provisional Application No. 60/168,658, filed Dec. 2, 1999, both of which are incorporated by reference herein in their entireties and relied upon.

[0002] The present invention relates to a method of control of parasites in animals, compositions comprising a compound effective for the said control and compounds effective against parasites.

[0003] It is generally a goal of agronomists and veterinarians to possess sufficient means to control pests, particularly arthropods, when they attempt to invade or attack mammals, particularly domestic animals and/or livestock. A classical method of controlling such pests has been the use of topical and/or systemic pesticides on or in the domestic animal which is being attacked. Generally effective treatments include the oral administration of insect growth regulators, such as lufenuron, or antihelminth compounds such as an ivermectin or an avermectin, or the topical application of the insecticide fipronil. It is advantageous to apply pesticides to animals in oral form so as to prevent the possible contamination of humans or the surrounding environment.

[0004] It is an object of the present invention to provide new pesticides which may be used in domestic animals.

[0005] Another object of the invention is to provide safer pesticides for domestic animals.

[0006] Another object of the invention is to provide new pesticides for domestic animals that may be used in lower doses than existing pesticides.

[0007] These objects are met in whole or in part by the present invention.

[0008] U.S. Pat. No. 5,079,370, EP-A 0846686, WO 98/24769 and WO 97/28126 disclose the use of arylpyrazoles as parasiticidal agents. However, these references are completely silent on the problem that antiparasitical agents often elicit emesis in the animal to be protected or cured from the parasites.

[0009] The present invention provides a method of controlling parasites in or on an animal comprising administering, preferably orally, to the animal a parasiticidally effective, substantially non-emetic amount of a 1-arylpyrazole of formula (I):

[0010] wherein:

[0011] R₂₀₁ is cyano, C(O)alkyl, C(S)NH₂, C(NH)OR₂₀₃, C(NH)SR₂₀₃, alkyl, C(═NOH)NH₂, C(═NNH₂)NH₂, C(O)NH₂, C(O)NHR₂₀₅, C(O)NR₂₀₅R₂₀₆, haloalkyl or heterocyclyl from the group:

[0012] optionally substituted by R₂₀₃;

[0013] R₂₀₂ is S(O)_(h)R₂₀₃, C₂-C₆ alkenyl, C₂-C₆ haloalkenyl, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl, C₂-C₆ alkynyl, nitro or imidazol-2-yl optionally substituted by alkyl, alkoxy, haloalkyl, halogen, cyano and/or nitro;

[0014] R₂₀₃ is alkyl or haloalkyl;

[0015] R₂₀₄ is —OH, R₂₀₅O—, HC(O)O—, R₂₀₅C(O)O—, R₂₀₅OC(O)O—, NH₂C(O)O—, R₂₀₅NHC(O)O—, R₂₀₅R₂₀₆NC(O)O—, R₂₀₅S(O)_(n)C(O)O—, R₂₀₆SO₂O—, aryl-SO₂O—, (C₄-C₇)-oxacycloalkyloxy, R₂₀₅R₂₀₆N—C(NR₂₀₅)—O—, R₂₀₅R₂₀₆N—C(NH)—O—, R₂₀₅NH—C(NR₂₀₅)—O₇, R₂₀₅NH—C(NH)—O—, R₂₀₅N═CH—O—, R₂₀₅N═C(R₂₀₆)—O—, R₂₀₅NH—C(S)—O—, R₂₀₅R₂₀₆N—C(S)—O—;

[0016] R₂₀₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl, C₂-C₆ alkynyl;

[0017] R₂₀₆ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted;

[0018] or R₂₀₅ and R₂₀₆ may form together with the nitrogen to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;

[0019] X₁ is selected from nitrogen and C—R₂₁₂; R₂₁₁, R₂₁₂ are independently selected from halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;

[0020] R₂₁₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅ or forms a ring with R₂₁₄;

[0021] R₂₁₄ is hydrogen or may constitute together with R₂₁₃ a group of OCF₂O, CF₂OCF₂, CF₂OCF₂O and CF₂CF₂O, which forms together with the carbons they are attached to a five to six membered ring; and

[0022] h, k and n are independently selected from 0, 1, and 2;

[0023] and veterinarily acceptable salts thereof.

[0024] By the term “veterinarily acceptable salts” is meant salts the anions of which are known and accepted in the art for the formation of salts for veterinary use. Suitable acid addition salts, e.g. formed by compounds of formula (I) containing a basic nitrogen atom, e.g. an amino group, include salts with inorganic acids, for example hydrochlorides, sulphates, phosphates and nitrates and salts with organic acids for example acetic acid.

[0025] When R₂₀₄ is OH the pyrazole structure can also be exhibited by its tautomeric form as pyrazolon structure.

[0026] Unless otherwise specified, alkyl and alkoxy groups are straight chain or branched and are generally lower alkyl and alkoxy groups, that is having from one to six carbon atoms, preferably from one to four carbon atoms. Generally, the haloalkyl, haloalkoxy and haloalkylamino groups have from one to four carbon atoms. Halogen means F, Cl, Br, and I, preferably F and Cl. The haloalkyl and haloalkoxy and haloalkylamino groups can bear one or more halogen atoms; preferred groups of this type include —CF₃ and —OCF₃. Cycloalkyl groups generally have from 3 to 6 carbon atoms, preferably from 3 to 5 carbon atoms and may be substituted by one or more halogen atoms. Preferably in compounds of formula (I), alkyl groups are generally substituted by from one to five halogen atoms, preferably from one to three halogen atoms. Chlorine and fluorine atoms are preferred.

[0027] In compounds of formula (I) the following examples of radicals are provided:

[0028] An example of cycloalkylalkyl is cyclopropylmethyl;

[0029] an example of cycloalkoxy is cyclopropyloxy; and

[0030] an example of alkoxyalkyl is CH₃OCH₂—.

[0031] Generally, in dialkylamino or di(haloalkyl)amino radicals, the alkyl and haloalkyl groups on nitrogen may be chosen independently of one another.

[0032] Generally, the term “aryl” means a carbocyclic aromatic radical having preferably 6 to 14, in particular 6 to 12, carbon atoms, for example phenyl, naphthyl or biphenylyl, preferably phenyl;

[0033] the term “heterocyclyl” preferably means a hetaryl or heteroaliphatic ring system, “hetaryl” preferably being understood as meaning an aryl radical in which at least one CH group is replaced by N and/or at least two adjacent CH groups are replaced by S, NH or O, for example a radical of thiophene, furan, pyrrole, thiazole, oxazole, imidazole, isothiazole, isoxazole, pyrazole, 1,3,4-oxadiazole, 1,3,4-thiadiazole, 1,3,4-triazole, 1,2,4-oxadiazole, 1,2,4-thiadiazole, 1,2,4-triazole, 1,2,3-triazole, 1,2,3,4-tetrazole, benzo[b]thiophene, benzo[b]furan, indole, benzo[c]thiophene, benzo[c]furan, isoindole, benzoxazole, benzothiazole, benzimidazole, benzisoxazole, benzisothiazole, benzopyrazole, benzothiadiazole, benzotriazole, dibenzofuran, dibenzothiophene, carbazole, pyridine, pyrazine, pyrimidine, pyridazine, 1,3,5-triazine, 1,2,4-triazine, 1,2,4,5-triazine, quinoline, isoquinoline, quinoxaline, quinazoline, cinnoline, 1,8-naphthyridine, 1,5-naphthyridine, 1,6-naphthyridine, 1,7-naphthyridine, phthalazine, pyridopyrimidine, purine, pteridine or 4H-quinolizine; and the term “heteroaliphatic ring system” preferably means a (C₃-C₈)cycloalkyl radical in which at least one carbon unit is replaced by O, S or a group NR′ and R′ is hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkanoyl, (C₁-C₄)alkoxycarbonyl, (C₁-C₄)alkylsulfonyl, (C₁-C₄)alkoxy or aryl.

[0034] The substituents with which the various aliphatic, cycloaliphatic, aromatic and heterocyclic ring systems can be provided are, for example, halogen, nitro, cyano, di-(C₁-C₄)alkylamino, (C₁-C₄)alkyl, (C₃-C₈)cycloalkyl, (C₁-C₄)trialkylsilyl, (C₁-C₄)alkoxy, (C₁-C₄)alkoxy-(C₁-C₄)alkyl, (C₁-C₂)alkoxy-[CH₂CH₂O]_(0,1,2)-ethoxy, (C₁-C₄)alkylthio, (C₁-C₄)alkylsulfinyl, (C₁-C₄)alkylsulfonyl, phenyl, benzyl, phenoxy, halophenoxy, (C₁-C₄)alkylphenoxy, (C₁-C₄)alkoxyphenoxy, phenylthio, heterocyclyl, heterocyclylthio or heterocyclyloxy, it being possible for one or more, in the case of fluorine also up to the maximum number of, hydrogen atoms in the alkyl radicals and the radicals derived therefrom to be replaced by halogen, preferably chlorine or fluorine, where, in the event that these substituents are (C₁-C₄)alkyl, they may also be linked cyclically and where one or two aliphatic carbon units in these fused ring systems, such as, for example, the indane, di-, tetra- or decahydronaphthyl or benzocycloheptane system, may be replaced by heteroatom units such as oxygen or sulfur and where one or more, in the case of fluorine also up to the maximum number of, hydrogen atoms on the aliphatic carbon atom units can be replaced by halogen or (C₁-C₄)alkyl.

[0035] It is also to be understood that enantiomeric and diastereomeric forms of the compounds of formulae (I) and salts thereof are embraced by the present invention.

[0036] By the term non-emetic is meant a compound that does not generally elicit emesis from the animal when a protective, preventative or cleaning dose is administered to the animal. By the term emesis is meant vomiting. Generally an emetic substance elicits the said emesis in less than 24 hours after administration, preferably less than 8 hours, more preferably less than 2 hours. Generally when the compounds of the invention are administered to a population of animals, more than 70% of the animals are free of emesis, preferably more than 80%, most preferably more than 90%.

[0037] Preferred compounds of the formula (I) are those wherein:

[0038] R₂₀, is cyano, C(O)alkyl, C(S)NH₂, alkyl, C(═NOH)NH₂ or C(═NNH₂)NH₂;

[0039] R₂₀₂ is S(O)_(h)R₂₀₃, C₂-C₃ alkenyl, C₂-C₃ haloalkenyl, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl, C₂-C₃ alkynyl;

[0040] R₂₀₃ is alkyl or haloalkyl;

[0041] R₂₀₄ is —OH, R₂₀₅O—, HC(O)O—, R₂₀₅C(O)O—, R₂₀₅OC(O)O—, NH₂C(O)O—,

[0042] R₂₀₅NHC(O)O—, R₂₀₅R₂₀₆NC(O)O—, R₂₀₅S(O)_(n)C(O)O—;

[0043] R₂₀₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl,

[0044] R₂₀₆ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, or R₂₀₅ and R₂₀₆ may form together with the nitrogen to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;

[0045] X₁ is selected from nitrogen and C—R₂₁₂;

[0046] R₂₁₁, R₂₁₂ are independently selected from halogen, hydrogen, CN, and NO₂;

[0047] R₂₁₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅

[0048] R₂₁₄ is hydrogen; and

[0049] h, k and n are independently selected from 0, 1, and 2.

[0050] Further compounds of formula (I) which are preferred according to the present invention are those wherein:

[0051] R₂₀₁ is cyano;

[0052] R₂₀₂ is S(O)_(h)R₂₀₃;

[0053] R₂₀₃ is alkyl or haloalkyl;

[0054] R₂₀₄ is OH or R₂₀₅O;

[0055] X₁ is selected from nitrogen and C—R₂₁₂;

[0056] R₂₁₁ and R₂₁₂ are independently selected from halogen, hydrogen, CN and NO₂;

[0057] R₂₁₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅; and

[0058] h and k are independently selected from 0, 1, and 2.

[0059] The compounds of formula (I) of the present invention preferably have one or more of the following features:

[0060] R₂₀₁ is cyano;

[0061] R₂₀₃ is halomethyl, preferably CF₃;

[0062] R₂₁₁ and R₂₁₂ are independently halogen;

[0063] X₁ is C—R₂₁₂;

[0064] R₂₁₃ is haloalkyl, haloalkoxy or —SF₅; or

[0065] h is 0 or 1, or 2.

[0066] A further embodiment of the invention includes compounds of the formula (I), with the proviso that if R₂₀₁ is CN and R₂₀₂ is S(O)_(h)R₂₀₃ then R₂₀₄ is not R₂₀₅O or R₂₀₅R₂₀₆N—C(O)—O—.

[0067] In another aspect of the present invention there is provided a method of controlling parasites in or on an animal by administering to the animal an 1-arylpyrazole of formula (II):

[0068] wherein:

[0069] R₂₁ is cyano, C(═S)NH₂, C(═NOH)NH₂ or C(═NNH₂ )NH₂;

[0070] R₂₂ is S(O)_(m)R₂₃;

[0071] R₂₃ is alkyl or haloalkyl;

[0072] R₂₄ is OH, HC(O)O—, R₂₅C(O)O—, R₂₅OC(O)O—, R₂₅R₂₅—N—C(O)—O— or

[0073] R₂₅S(O)_(n)C(O)O—;

[0074] R₂₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl, C₂-C₆ alkynyl;

[0075] or two groups R₂₅ may form together with the nitrogen to which they are attached a 3 to 7 membered ring which additionally may contain one or more heteroatoms selected from nitrogen, oxygen and sulfur;

[0076] X is selected from nitrogen and C—R₃₂;

[0077] R₃₁ and R₃₂ are independently selected from halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;

[0078] R₃₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_(r)CF₃, and —SF₅ or forms a ring together with R₃₄;

[0079] R₃₄ is hydrogen or may constitute together with R₂₁₃ a group of OCF₂O; CF₂OCF₂, CF₂OCF₂O and CF₂CF₂O, which forms together with the carbons they are attached to a five to six membered ring;

[0080] m is 0, 1 or 2;

[0081] r is selected from 0, 1, and 2;

[0082] and veterinarily acceptable salts thereof;

[0083] provided that if R₂₁ is cyano then R₂₄ is not R₂₅R₂₅—N—C(O)—O—.

[0084] Preferred are compounds of formula (II), wherein:

[0085] R₂₁ is cyano, C(═S)NH₂, C(═NOH)NH₂ or C(═NNH₂)NH₂;

[0086] R₂₂ is S(O)_(m)R₂₃;

[0087] R₂₃ is alkyl or haloalkyl;

[0088] R₂₄ is OH, HC(O)O—, R₂₅C(O)O—, R₂₅OC(O)O— or R₂₅S(O)_(n)C(O)O—;

[0089] R₂₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl;

[0090] X is selected from nitrogen and C—R₃₂;

[0091] R₃₁ and R₃₂ are independently selected from halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂;

[0092] R₃₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_(r)CF₃, and —SF₅.

[0093] In another aspect of the present invention there is provided a compound of formula (II) or salt thereof as hereinbefore described with the proviso that the compound is not 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylthio-5-hydroxypyrazole.

[0094] A further preferred class of compounds of formula (II) are those wherein:

[0095] R₂₁ is cyano;

[0096] R₂₂ is S(O)_(m)R₂₃;

[0097] R₂₃ is haloalkyl, preferably CF₃;

[0098] R₂₄ is OH;

[0099] X is selected from nitrogen and C—R₃₂;

[0100] R₃₁ and R₃₂ are independently selected from halogen,

[0101] R₃₃ is selected from halogen, haloalkyl, haloalkoxy, —S(O)_(r)CF₃, and —SF₅;

[0102] m and r are independently selected from 0, 1, and 2

[0103] with the proviso that the compound is not 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylthio-5-hydroxypyrazole.

[0104] In a further aspect of the invention the following groups of compounds are provided:

[0105] Compounds of the formula (I), wherein

[0106] R₂₀₁ is C(O)NH₂, C(O)NHR₂₀₅, C(O)NR₂₀₅R₂₀₆, C(O)N═S(R₂₀₃)₂, haloalkyl or heterocyclyl from the group:

[0107] optionally substituted by R₂₀₃;

[0108] Compounds of the formula (I), wherein R₂₀₂ is nitro or imidazol-2-yl optionally substituted by alkyl, alkoxy, haloalkyl, halogen, cyano, nitro;

[0109] Compounds of the formula (I), wherein R₂₀₄ is R₂₀₆SO₂O—, aryl-SO₂O—, (C₄-C₇)-oxacycloalkyloxy, R₂₀₅R₂₀₆N—C(NR₂₀₅)—O—, R₂₀₅R₂₀₆N—C(NH)—O—, R₂₀₅NH—C(NR₂₀₅)—O—, R₂₀₅NH—C(NH)—O—, R₂₀₅N═CH—O—, R₂₀₅N═C(R₂₀₆)—O—, R₂₀₅NH—C(S)—O—, R₂₀₅R₂₀₆N—C(S)—O—;

[0110] Compounds of the formula (I), wherein R₂₁₄ constitute together with R₂₁₃ a group of OCF₂O, CF₂OCF₂, CF₂OCF₂O and CF₂CF₂O, which forms together with the carbons they are attached to a five to six membered ring.

[0111] The compounds 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluromethylsulfinyl-5-hydroxypyrazole and 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluromethylsulfonyl-5-hydroxypyrazole are highly preferred compounds according to the invention.

[0112] The following compounds of formula (I) are preferred according to the present invention as listed in Tables 1 to 3. The Compound Numbers are for identification purposes only. The following symbols are hereby defined: Me means methyl; Et means ethyl; n-Pr means n-propyl; i-Pr means isopropyl; n-Bu means n-Butyl; and Ph means Phenyl. TABLE 1 Compounds of formula (I) wherein R₂₀₁ is cyano; R₂₀₂ is SCF₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅. Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound Compound Number Number (R₂₁₃ = CF₃) (R₂₁₃ = SF₅) R₂₀₄ Phys. data  1-1  1-2 OH 19F: −44.9 −63.8  2-1  2-2 OMe mp. 83  3-1  3-2 OEt mp. 105  4-1  4-2 OPr  5-1  5-2 O-i-Pr  6-1  6-2 O-n-Bu  7-1  7-2 OCH₂OMe  8-1  8-2 OCH₂CH₂OMe  9-1  9-2 OCH₂OEt 10-1 10-2 OCH₂CH₂OEt 11-1 11-2 OC(O)Me 12-1 12-2 OC(O)Et 13-1 13-2 OC(O)n-Pr 14-1 14-2 OC(O)H 15-1 15-2 OC(O)NH₂ 16-1 16-2 OC(O)NHMe 17-1 17-2 OC(O)NHEt 18-1 18-2 OC(O)NHnPr 19-1 19-2 OC(O)NMe₂ mp. 126

[0113] TABLE 2 Compounds of formula (I) wherein R₂₀₁ is cyano; R₂₀₂ is SOCF₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅. Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound Compound Number Number (R₂₁₃ = CF₃) (R₂₁₃ = SF₅) R₂₀₄ Phys. data  1-3  1-4 OH mp. 185  2-3  2-4 OMe mp. 136  3-3  3-4 OEt mp. 157  4-3  4-4 OPr  5-3  5-4 O-i-Pr  6-3  6-4 O-n-Bu  7-3  7-4 OCH₂OMe  8-3  8-4 OCH₂CH₂OMe  9-3  9-4 OCH₂OEt 10-3 10-4 OCH₂CH₂OEt 11-3 11-4 ONa 19F: −60.9 −72.6 12-3 12-4 OC(O)Et 13-3 13-4 OC(O)n-Pr 14-3 14-4 OC(O)H 15-3 15-4 OC(O)NH₂ 16-3 16-4 OC(O)NHMe 17-3 17-4 OC(O)NHEt 18-3 18-4 OC(O)NHnPr 19-3 19-4 OC(O)NMe₂

[0114] TABLE 3 Compounds of formula (I) wherein R₂₀₁ is cyano; R₂₀₂ is SO₂CF₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃ or SF₅. Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound Compound Number Number (R₂₁₃ = CF₃) (R₂₁₃ = SF₅) R₂₀₄ Phys. data  1-5  1-6 OH 19F: −63.8 −79.9  2-5  2-6 OMe mp. 151  3-5  3-6 OEt mp. 132  4-5  4-6 OPr  5-5  5-6 O-i-Pr  6-5  6-6 O-n-Bu  7-5  7-6 OCH₂OMe  8-5  8-6 OCH₂CH₂OMe  9-5  9-6 OCH₂OEt 10-5 10-6 OCH₂CH₂OEt 11-5 11-6 OC(O)Me 12-5 12-6 OC(O)Et 13-5 13-6 OC(O)n-Pr 14-5 14-6 OC(O)H 15-5 15-6 OC(O)NH₂ 16-5 16-6 OC(O)NHMe 17-5 17-6 OC(O)NHEt 18-5 18-6 OC(O)NHnPr 19-5 19-6 OC(O)NMe₂

[0115] TABLE 4 Compounds of formula (I) wherein R₂₀₁ is alkyl or haloalkyl; R₂₀₂ is SO_(h)R₂₀₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound No R₂₀₁ R₂₀₂ R₂₀₄ Phys. Data  1-7 CH₃ SCF₃ OH 19F: −45.9 −63.5  2-7 CH₃ SOCF₃ OH  3-7 CH₃ SO₂CF₃ OH  4-7 CH₃ SCClF₂ OH 19F: −30.4 −63.7  5-7 CH₃ SOCClF₂ OH  6-7 CH₃ SO₂CClF₂ OH  7-7 CH₃ SCCl₂F OH  8-7 CH₃ SOCCl₂F OH  9-7 CH₃ SC₂F5 OH 10-7 CH₃ SC₂H5 OH 11-7 CH₃ SCF₃ OMe 12-7 CH₃ SCF₃ OEt 13-7 CH₃ SMe OH 14-7 C₂H₅ SCF₃ OH 15-7 CF₃ SCF₃ OH 16-7 CHF₂ SCF₃ OH 17-7 CF₃ SOCF₃ OH 18-7 CF₃ SO₂CF₃ OH 19-7 CF₃ SCClF₂ OH 20-7 CF₃ SCCl₂F OH

[0116] TABLE 5 Compounds of formula (I) wherein R₂₀₂ is SO_(h)R₂₀₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound No R₂₀₁ R₂₀₂ R₂₀₄ Phys. data  1-8 CONH₂ SCF₃ OH mp. 197  2-8 CONH₂ SOCF₃ OH  3-8 CONH₂ SO₂CF₃ OH  4-8 CSNH₂ SCF₃ OH mp. 150  5-8 CSNH₂ SOCF₃ OH  6-8 CSNH₂ SO₂CF₃ OH  7-8 CONMe₂ SCF₃ OH  8-8 C(NOH)NH₂ SCClF₂ OH mp. 156  9-8 C(NOH)NH₂ SCF₃ OH mp. 184 10-8 COCH₃ SCF₃ OH 19F: −44.5 −61.7 11-8 COCH₃ SCClF₂ OH 19F: −29.4 −61.0 12-8 CONH₂ SCF₃ OEt 13-8 CONH₂ SCClF₂ OEt 14-8 Oxadiazolin-3-yl SCF₃ OH 15-8 Oxazolin-2-yl SCF₃ OH 16-8 CON═S(iPr₂) SCF₃ OH 17-8 CON═S(iPr)₂ SOCF₃ OH 18-8 CON═S(iPr)₂ SO2CF₃ OH 19-8 CONH₂ SCF₃ OMe mp. 148-151

[0117] TABLE 6 Compounds of formula (I) wherein R₂₀₁ is CN; R₂₀₂ is SO_(h)R₂₀₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Com- pound No R₂₀₂ R₂₀₄ Phys. data  1-9 SCClF₂ OH 19F: −30.7 −63.7  2-9 SOCClF₂ OH  3-9 SO₂CClF₂ OH  4-9 SCCl₂F OH  5-9 SOCCl₂F OH  6-9 SO₂CCl₂F OH  7-9 SC₂F₅ OH  8-9 SCH₂CF₃ OH  9-9 SCCl₂CF₃ OH 10-9 SCCl₂CH₃ OH 11-9 SC₂H₅ OH 1H: 1.25, 3H; 2.71, 3H; 7.72, 2H; 12-9 SCHF₂ OH 13-9 SCClF₂ OEt mp. 91 14-9 SOCClF₂ OEt mp. 161 15-9 SCClF₂ OCONMe₂ 16-9 SCClF₂ OCOtBu 17-9 SCH₃ OH mp. 66 18-9 SCH₃ OCONMe₂ 1H: 2.43, 3H; 2.96, 6H; 7.75, 2H; 19-9 SCBrF₂ OH 20-9 SCCl₃ OH 21-9 SCCl₂F OMe mp. 154 22-9 SOCCl₂F OMe mp. 136 23-9 SO₂CCl₂F OMe mp. 189 24-9 SO₂CClF₂ OEt mp. 130 25-9 SCClF₂ OMe mp. 87 26-9 SOCClF₂ OMe mp. 139 27-9 SO₂CClF₂ OMe mp. 166

[0118] TABLE 7 Compounds of formula (I) wherein R₂₀₁ is CN; R₂₀₂ is SO_(h)R₂₀₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound No R₂₀₂ R₂₀₄ Phys. data  1-10 SCF₃ OCH₂—CCH 19F: −44.6 −63.8  2-10 SCF₃ OCH₂COOEt mp. 71  3-10 SCF₃ OCOtBu mp. 82  4-10 SCF₃ OCO—Ph-4-OMe 19F: −43.5 −63.9  5-10 SCF₃ OSO₂Me mp. 110  6-10 SCF₃ OCO-Pyrrolidin mp. 101  7-10 SCF₃ OCO-Morpholin 19F: −43.5 −63.8  8-10 SCF₃ OCO—N(i-Pr)₂ mp. 120  9-10 SCF₃ OCO-NPh₂ mp. 142 10-10 SCF₃ OCO-N(Me)Ph 19F: −43.6 −63.7 11-10 SCF₃ OCO-Carbazol mp. 148 12-10 SCF₃ OCO-Adamantyl mp. 142 13-10 SCF₃ OCO-Mesityl mp. 103 14-10 SCF₃ OCH₂Ph mp. 73 15-10 SCF₃ OSO₂-4-Tolyl 16-10 SCF₃ O—C(NMe)NMe₂ 17-10 SCF₃ O—CH═NC₂H₄OEt 18-10 SCF₃ OCH₂CONH₂ mp. 156 19-10 SCF₃ O—C(N(i-Pr))NHiPr 20-10 SCF₃ O—C(S)-NHEt

[0119] TABLE 8 Compounds of formula (I) wherein R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is CF₃; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound No R₂₀₁ R₂₀₂ R₂₀₄ Phys. data  1-11 CN 4,5-Dicyanoimidazol-2-yl OH  2-11 CN 4,5-Dicyanoimidazol-2-yl OEt  3-11 CH₃ 4,5-Dicyanoimidazol-2-yl OH  4-11 CH₃ 4,5-Dicyanoimidazol-2-yl OEt 1H: 1.28, 3H; 2.55, 3H; 4.08, 2H; 7.77, 2H;  5-11 CN —CH═CCl₂ OEt  6-11 CN —CH₂CH=CH₂ OAllyl mp. 62-66  7-11 CN —CH═CBr₂ OEt  8-11 CN Cyclopropyl OEt  9-11 CN c—C₆H₁₁ OEt 10-11 CN NO₂ OH mp. 107 11-11 CN NO₂ OEt 12-11 CN —CC—Me OEt 13-11 CN —CC—SiMe₃ OEt

[0120] TABLE 9 Compounds of formula (I) wherein R₂₀₁ is CN; R₂₀₂ is SO_(h)R₂₀₃; R₂₁₁ is Cl, R₂₁₄ and R₂₁₃ form the unit CF₂OCF₂; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound No R₂₀₂ R₂₀₄ X = CR₂₁₂ Phys. data  1-12 SCF₃ OH CH  2-12 SCF₃ OH C—Cl  3-12 SCF₃ OEt C—Cl  4-12 SOCF₃ OH CH  5-12 SOCF₃ OH C—Cl  6-12 SO₂CF₃ OH CH  7-12 SO₂CF₃ OH C—Cl  8-12 SCClF₂ OH C—Cl  9-12 SCCl₂F OH C—Cl 10-12 SC₂H₅ OH C—Cl

[0121] TABLE 10 Compounds of formula (I) wherein R₂₀₁ is CN; R₂₀₂ is SO_(h)R₂₀₃; R₂₁₁ is Cl, X₁ is C—Cl, R₂₁₄ is H and R₂₁₃ is OCF₃; Phys. data: melting point (° C.) or NMR (¹H, ¹⁹F-NMR, ppm) Compound No R₂₀₂ R₂₀₄ Phys data  1-13 SCF₃ OH  2-13 SOCF₃ OH  3-13 SO₂CF₃ OH  4-13 SCF₃ OMe mp. 101  5-13 SOCF₃ OMe mp. 104  6-13 SO₂CF₃ OMe mp. 117  7-13 SCCl₂F OMe mp. 123  8-13 SCF₃ OEt  9-13 SOCF₃ OEt 10-13 SO₂CF₃ OEt

METHODS OF SYNTHESIS Method 1

[0122] The compounds of formula (I) and (II) with R₂₀₄/R₂₄═OH and R₂₂═SR₂₃ can be synthesized by reacting 5-hydroxypyrazoles with sulfenylchlorides with or without bases in organic solvents (see e.g. EP-A-295 117):

[0123] The compounds of formula (I) and (II) with R₂₀₄/R₂₄═OH and R₂₂═SR₂₃ can be synthesized by reacting 5-hydroxypyrazoles with disulfur dichloride. The resulting pyrazoledisulfides can be alkylated to yield 4-pyrazolsulfides (see e.g., EP-A-374 061, EP295117, C. Wakselman, J. Chem. Soc. Perkin Trans 1, 1992, 3371-3375):

Method 3

[0124] The compounds of formula (I) and (II) with R₂₀₄/R₂₄═OH and R₂₂═S(O)_(a)R₂₃ (a=1,2) can be synthesized by reacting pyrazolsulfides R₂₂═SR₂₃ with oxidizing agents like peroxy compounds (hydrogen peroxide, organic peroxides as peroxyacetic acid), halogen derivatives (like periodate salts) and others to obtain sulfoxides R₂₂═SOR₂₃ and sulfones R₂₂═SO₂R₂₃ (see e.g. EP-A-295 117).

[0125] In another aspect of the present invention, compounds of formula (II) wherein R₂₄ is HC(O)O—, R₂₅C(O)O—, R₂₅OC(O)O—, or R₂₅S(O)_(n)C(O)O and R₂₁, R₂₂, R₃₁, R₃₃, X and n are defined above are generally prepared by reaction of compounds of formula (II) wherein R₂₄ is OH and R₂₁, R₂₂, R₃₁, R₃₃, X and n are defined above with compounds of formulae (III), (IV), (V), and (VI) respectively wherein X₂ is a leaving group such as a halogen atom or an acetyl group:

HC(O)X₂  (III)

R₂₅C(O)X₂  (IV)

R₂₅OC(O)X₂  (V)

R₂₅S(O)_(n)C(O)X₂  (VI)

[0126] Compounds of general formula (II) wherein R₂₄ is OH and R₂₁, R₂₂, R₃₁, R₃₃, X and n are defined above may be prepared by methods known in the art generally or by methods described in International Patent Publications WO 94/21606, WO 97/07102, WO 98/24767, WO 98/28277, WO 98/28278 and WO 98/28279, European Patent Application 385809, and U.S. Pat. No. 5,232,940, 5,047,550 or other methods known to the person skilled in the art.

[0127] The present invention also relates to a composition comprising a parasiticidally effective, substantially non-emetic amount of a compound of formula (I) or a salt thereof and an acceptable carrier. Acceptable carriers for the use of the compounds are generally known to the skilled addressee concerned with pest control in animals, particularly domestic animals, most preferably dogs or cats.

[0128] The compositions which can be used in the invention can comprise generally from about 0.001 to 95% of the compound of formula (I) or a salt thereof. The remainder of the composition up to 100% comprises a carrier as well as generally various additives. In this specification and the accompanying claims, percentages are by weight.

[0129] The diluted liquid formulations generally comprise from about 0.001 to about 3% of compound of formula (I) or a salt thereof, preferably from about 0.1 to about 0.5%.

[0130] Solid formulations generally comprise from about 0.1 to about 8% of compound of formula (I) or a salt thereof, preferably from about 0.5 to about 1.5%.

[0131] Compositions for oral administration comprise one or more of the compounds of general formula (I) or salts thereof in association with veterinarily acceptable carriers or coatings and include, for example, tablets, pills, capsules, gels, drenches, medicated feeds, medicated drinking water, medicated dietary supplements, slow-release boluses or other slow-release devices intended to be retained within the gastro-intestinal tract. Any of these may incorporate the active ingredients contained within micro-capsules or coated with acid-labile or alkali-labile or other pharmaceutically acceptable enteric coatings. Feed premixes or concentrates containing compounds of the present invention for use in preparation of medicated diets, drinking water or other materials for consumption by animals may also be used. In a highly preferred embodiment, the compositions are administered postprandially, preferably from just after a meal to 2 hours after the meal.

[0132] In a highly preferred embodiment, there is provided a product which is readily chewed by the animal and which product does generally not allow human contamination when the product is provided to the animal by hand.

[0133] The compounds of general formula (I) or salts thereof may be administered before, during or after meals. The compounds of general formula (I) or salts thereof may be mixed with a carrier and/or a foodstuff.

[0134] According to the present invention the compound of formula (I) or a salt thereof is administered orally in a dose to the animal in a dose range generally from 0.1 to 500 mg/kg of the compound of formula (I) or a salt thereof per kilogram of animal body weight (mg/kg), preferably from 1 to 100 mg/kg, more preferably from 1 to 50 mg/kg , even more preferably from 2 to 25 mg/kg, most preferably from 3 to 15 mg/kg.

[0135] According to the present invention, the frequency of treatment of the animal, preferably the domestic animal to be treated by the compound of formula (I) or a salt thereof is generally from about once per week to about once per year, preferably from about once every two weeks to about once every six months, more preferably from about once every two weeks to once every three months, and most preferably from about once every two weeks to about once every six weeks.

[0136] Generally the animal to be treated is a domestic animal, preferably a domestic companion animal. More preferably the animal to be treated is a dog and/or a cat.

[0137] Accordingly, in a preferred embodiment there is provided a method of controlling parasites in or on a cat comprising administering orally to the cat a parasitically effective, substantially non emetic amount of a 1-arylpyrazole of formula (I).

[0138] In a further preferred embodiment there is provided a method of controlling parasites in or on a dog comprising administering orally to the dog a parasitically effective, substantially non emetic amount of a 1-arylpyrazole of formula (I).

[0139] The present invention also relates to a composition comprising a parasiticidally effective amount of a compound of formula (II) or a salt thereof and an acceptable carrier. Acceptable carriers for the use of the compounds are generally known to the skilled addressee concerned with pest control in animals, particularly domestic animals, most preferably dogs or cats.

[0140] In another aspect of the present invention, the compounds of formula (II) or salts thereof may be used in the field of veterinary medicine or livestock husbandry or in the maintenance of public health against arthropods, helminths or protozoa which are parasitic internally or externally upon vertebrates, particularly warm-blooded vertebrates, for example domestic animals, e.g., cattle, sheep, goats, equines, swine, poultry, dogs or cats.

[0141] The compounds are administered to animals infested by or exposed to infestation by arthropods, helminths or protozoa, by parenteral, oral or topical application of compositions in which the active ingredient exhibits an immediate and/or prolonged action over a period of time against the arthropods, helminths or protozoa, for example by incorporation in feed or suitable orally-ingestible pharmaceutical formulations, edible baits, salt licks, dietary supplements, pour-on formulations, sprays, baths, dips, showers, jets, dusts, greases, shampoos, creams, wax smears or livestock self-treatment systems.

[0142] Solid or liquid compositions for application topically to animals, timber, stored products or household goods usually contain from about 0.00005% to about 90%, more particularly from about 0.001% to about 10%, by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. For administration to animals orally or parenterally, including percutaneously, in solid or liquid compositions, these normally contain from about 0.1% to about 90% by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Medicated feedstuffs normally contain from about 0.001% to about 3% by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Concentrates or supplements for mixing with feedstuffs normally contain from about 5% to about 90%, preferably from about 5% to about 50%, by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Mineral salt licks normally contain from about 0.1% to about 10% by weight of one or more compounds of formula (II) or veterinarily acceptable salts thereof.

[0143] Dusts or liquid compositions for application to livestock, goods, premises or outdoor areas may contain from about 0.0001% to about 15%, more especially from about 0.005% to about 2.0%, by weight, of one or more compounds of formula (II) or veterinarily acceptable salts thereof. Suitable concentrations in treated waters are between about 0.0001 ppm and about 20 ppm, more particularly about 0.001 ppm to about 5.0 ppm. of one or more compounds of formula (II), or veterinarily acceptable salts thereof, and may be used therapeutically in fish farming with appropriate exposure times. Edible baits may contain from about 0.01% to about 5%, preferably from about 0.01% to about 1.0%, by weight, of one or more compounds of formula (II) or veterinarily acceptable salts thereof.

[0144] When administered to vertebrates parenterally, orally or by percutaneous or other means, the dosage of compounds of formula (II), or veterinarily acceptable salts thereof, will depend upon the species, age, or health of the vertebrate and upon the nature and degree of its actual or potential infestation by arthropod, helminth or protozoan pests. A single dose of about 0.1 to about 500, preferably from 0.1 to about 100 mg, preferably about 2.0 to about 20.0 mg, per kg body weight of the animal or doses of about 0.01 to about 20.0 mg, preferably about 0.1 to about 5.0 mg, per kg body weight of the animal per day, for sustained medication, are generally suitable by oral or parenteral administration. By use of sustained release formulations or devices, the daily doses required over a period of months may be combined and administered to animals on a single occasion.

[0145] The compounds of the invention may be administered most advantageously with another parasiticidally effective material, such as an endoparasiticide, and/or an ectoparasiticide, and/or an endectoparasiticide. For example, such compounds include macrocyclic lactones such as avermectins or milbemycins e.g., ivermectin; pyratel (generally adminsitered as pyrantel pamoate) or an insect growth regulator such as lufenuron or methoprene.

[0146] By the term “parasites” as used in the specification and claims is meant endoparasites and ectoparasites of warm-blooded animals, particularly ectoparasites. Preferably, fleas and/or ticks are controlled by the method of the present invention.

[0147] Illustrative of specific parasites of various host animals which may be controlled by the methods of this invention include arthropods such as:

[0148] Mites: Mesostigmata spp. e.g., mesostigmatids such as the chicken mite, Dermanyssus gallinae; itch or scab mites such as Sarcoptidae spp. for example Sarcoptes scabiei; mange mites such as Psoroptidae spp. including Chorioptes bovis and Psoroptes ovis; chiggers e.g., Trombiculidae spp. for example the north american chigger, Trombicula alfreddugesi;

[0149] Ticks: e.g., soft-bodied ticks including Argasidae spp. for example Argas spp. and Ornithodoros spp; hard-bodied ticks including Ixodidae spp., for example Rhipicephalus sanguineus, and Boophilus spp.;

[0150] Lice: sucking lice, e.g., Menopon spp. and Bovicola spp.; biting lice, e.g., Haematopinus spp., Linognathus spp. and Solenopotes spp.;

[0151] Fleas: e.g., Ctenocephalides spp., such as dog flea (Ctenocephalides canis) and cat flea (Ctenocephalides felis); Xenopsylla spp. such as oriental rat flea [Xenopsylla cheopis]; and Pulex spp. such as human flea [Pulex irritans];

[0152] True bugs: e.g., Cimicidae or including the common bed bug (Cimex lectularius);, Triatominae spp. including triatomid bugs also known as kissing bugs; for example Rhodnius prolixus and Triatoma spp.;

[0153] bloodsucking adult flies: (e.g., horn fly [Haematobia irritans], horse fly [Tabanus spp.], stable fly [Stomoxys calcitrans], black fly [Simulium spp.], deer fly [Chrysops spp.], louse fly [Melophagus ovinus], tsetse fly [Glossina spp.], mosquitoes [Culex spp., Anopheles spp., and Aedes spp.); and

[0154] parasitic fly maggots: (e.g., bot fly [Oestrus ovis and Cuterebra spp.], blow fly [Phaenicia spp.], screwworm [Cochliomyia hominivorax], cattle grub [Hypoderma spp.], fleeceworm.

[0155] The present invention also provides for the use of a compound of formula (I) or a salt thereof hereinbefore described as a therapeutic agent, preferably for animals, more preferably for domestic animals.

[0156] The veterinary composition may be sterile or non-sterile. It may be a liquid (e.g., aqueous) or solid (e.g., dry) composition, in particular a freeze-dried composition, from which, by addition of water or another liquid, orally effective solutions may be prepared.

[0157] The present invention also provides for the use of a compound of formula (I) or a salt thereof as hereinbefore defined for the manufacture of a veterinary composition for the control of parasites in or on an animal.

[0158] In a further embodiment of the invention there is provided the use of a compound of formula (I) or salt thereof for controlling parasites in or on an animal without causing emesis of the animal.

[0159] Preferred is the use for orally administering the compound to the animal, which is preferably a domestic animal, highly preferred a cat or a dog.

[0160] In a further embodiment of the invention there is provided the use of a compound of formula (I) or salt thereof for the manufacture of a substantially non-emetic composition, for controlling parasites in or on an animal, preferably for oral administering.

[0161] The present invention also relates to a method of cleaning animals in good health comprising the application to the animal of a compound of formula (I) or a salt thereof as hereinbefore defined to the animal.

[0162] The method of cleaning an animal is not a method of treatment by therapy of the animal body per se, because

[0163] (a) the animal is in good health and requires no substantial treatment to correct a deficiency of health;

[0164] (b) the cleaning of the animal is not intended to be done by veterinary personnel, but by persons interested in the cleaning of the animal; and

[0165] (c) the purpose of such cleaning is to avoid unpleasant conditions for humans and the environment in which humans inhabit so as to not infest the said humans with arthropods carried by the animal.

[0166] By “carrier” is meant an organic or inorganic material, which can be natural or synthetic, and which is associated with the compound and which facilitates its application to the animal. This carrier is thus generally inert and should be arthropodicidally acceptable. The carrier can be solid (e.g., clay, silicates, silica, resins, wax) or liquid (e.g., water, alcohols, ketones, oil solvents, polar aprotic solvents). An example of an oil solvent is corn oil. An example of a polar aprotic solvent is dimethyl sulfoxide.

[0167] The compounds of the invention also have utility in the control of arthropod or nematode pests of plants. The active compound is generally applied to the locus in which arthropod or nematode infestation is to be controlled at a rate of about 0.005 kg to about 25 kg of active compound per hectare of locus treated, preferably 0.02 to 2 kg/ha. Under ideal conditions, depending on the pest to be controlled, the lower rate may offer adequate protection. On the other hand, adverse weather conditions, resistance of the pest and other factors may require that the active ingredient be used in higher proportions. For foliar application, a rate of 0.01 to 1 kg/ha may be used.

[0168] When the pest is soil-borne, the formulation containing the active compound is distributed evenly over the area to be treated in any convenient manner. Application may be made, if desired, to the field or crop-growing area generally or in close proximity to the seed or plant to be protected from attack. The active component can be washed into the soil by spraying with water over the area or can be left to the natural action of rainfall. During or after application, the formulation can, if desired, be distributed mechanically in the soil, for example by ploughing or disking. Application can be prior to planting, at planting, after planting but before sprouting has taken place or after sprouting.

[0169] The compounds of the invention may be applied in solid or liquid compositions to the soil principally to control those nematodes dwelling therein but also to the foliage principally to control those nematodes attacking the aerial parts of the plants (e.g., aphelenchoides spp. and ditylenchus spp. listed above).

[0170] The compounds of the invention are of value in controlling pests which feed on parts of the plant remote from the point of application, e.g., leaf feeding insects are killed by the subject compounds applied to roots. In addition the compounds may reduce attacks on the plant by means of antifeeding or repellent effects.

[0171] The compounds of the invention are of particular value in the protection of field, forage, plantation, glasshouse, orchard and vineyard crops, or ornamentals and of plantation and forest trees, for example, cereals (such as maize, wheat, rice, sorghum), cotton, tobacco, vegetables and salads (such as beans, cole crops, curcurbits, lettuce, onions, tomatoes and peppers), field crops (such as potato, sugar beet, ground nuts, soyabean, oil seed rape), sugar cane, grassland and forage (such as maize, sorghum, lucerne), plantations (such as of tea, coffee, cocoa, banana, oil palm, coconut, rubber, spices), orchards and groves (such as of stone and pip fruit, citrus, kiwifruit, avocado, mango, olives, and walnuts), vineyards, ornamental plants, flowers and shrubs under glass and in gardens and parks, forest trees (both deciduous and evergreen) in forests, plantations and nurseries.

[0172] They are also valuable in the protection of timber (standing, felled, converted, stored or structural) from attack by sawflies (e.g., urocerus) or beetles (e.g., scolytids, platypodids, lyctids, bostrychids, cerambycids, anobiids), or termites, for example, reticulitermes spp., heterotermes spp., coptotermes.

[0173] They have applications in the protection of stored products such as grains, fruits, nuts, spices and tobacco, whether whole, milled or compounded into products, from moth, beetle and mite attack. Also protected are stored animal products such as skins, hair, wool and feathers in natural or converted form (e.g., as carpets or textiles) from moth and beetle attack; also stored meat and fish from beetle, mite and fly attack.

[0174] The disclosure in U.S. provisional application No. 60/168,658 from which this application claims priority is incorporated herein by reference.

[0175] The invention is further illustrated by the following examples, without limiting it thereto.

EXAMPLES AND PREPARATIONS Example 1 Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfinyl-5-hydroxypyrazole

[0176] To a solution of 15 g (35.5 mmol) of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-hydroxypyrazole in 125 ml of dichloromethane at room temperature was added a solution of m-chloroperbenzoic acid (8.76 g, 70%, 35.5 mmol) in 375 ml of dichloromethane. The resulting solution was stirred at room temperature for 17 hr. It was then concentrated and triturated with ethyl acetate and heptane(1:2). Upon filtration a solid was obtained. This solid was dissolved in ethyl acetate and stirred with saturated sodium bicarbonate solution. The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layer was dried (magnesium sulfate) and concentrated. Upon chromatographic purification via silica gel column, a solid (5.7 g, 13.01 mol, 37%) was obtained as the desired product, mp 185-187d.

Example 2 Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole

[0177] To the solution of 2 g (4.74 mmol) of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-hydroxypyrazole in 1,2-dichloroethane was added 1.83 ml (9.52 mmol, 35% in acetic acid) of peracetic acid at room temperature. The resulting solution was heated up to 60 C for 9 hr. It was then cooled and concentrated to give 2.05 g of residue. Upon chromatographic purification via silica gel column eluting with gradient solvent mixture (heptane/ethyl acetate), an oil (1.08 g, 2.38 mmol, 50.2% yield ) was obtained as the desired product with 98% HPLC purity; F-NMR, −60.999 ppm (AR-CF₃), −79.893 ppm (SO₂CF₃). H-NMR, 8.18 ppm (s, 2H).

Example 3 Preparation of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-amido-4-trifluoromethylsulfenyl-5-hydroxypyrazole

[0178] To the mixture of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-hydroxypyrazole (3.0 g, 7.13 mmol) and concentrated sulfuric acid (3 ml) was heated at 100 C for 3 hr. The reaction mixture was cooled and poured into ice-water. A solid was collected via filtration and was washed with water. It was then vacuum dried to obtain a solid (2.88 g, 6.56 mmol, 92% yield) with 98% HPLC purity, m. p. 197-198 C.

Example 4 Preparation of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-thioamido-4-trifluoromethylsulfenyl-5-hydroxypyrazole

[0179] The mixture of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-amido-4-trifluoromethylsulfenyl-5-hydroxypyrazole (1 g, 2.28 mmol) and Lawesson's reagent (0.49 g, 1.21 mmol) in toluene was heated up to reflux for 4 hr. The reaction mixture turned into a solution during this time. This solution was then cooled, concentrated, and purified via chromatographic purification to provide a solid (0.283 g, 0.623 mmol, 27.3% yield) with 96% HPLC purity m. p. 150-151 decomp.

Example 5 Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-oximicamido-4-trifluoromethylsulfenyl-5-hydroxypyrazole

[0180] To the solution of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-hydroxypyrazole (3.0 g, 7.11 mmol) in 15 ml of methanol at room temperature was added hydroxyamine hydrochloride (0.59 g, 8.53 mmol) and triethylamine (0.94 g, 9.24 mmol). The resulting mixture was stirred at room temperature for a total of 48 hr with additional hydroxyamine hydrochloride (1.18 g, 17.06 mmol) and triethylamine (1.88 g, 18.5 mmol) added portionwise. The resulting reaction mixture was concentrated and then dissolved in ethyl acetate. The organic layer was washed with saturated ammonium chloride, water, dried (sodium sulfate), and concentrated to give a brown oil which solidified after standing, m. p. 184 C.

Example 6 Preparation of 1-(2,6-Dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-trimethylacetoxypyrazole

[0181] To the solution of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-hydroxypyrazole (7.00 g, 16.6 mmol) and pyridine (4.91 g, 62.1 mmol) in 1,2-dichloroethane at room temperature was added trimethylacetyl chloride (4.37 g, 36.2 mmol) dropwise. Ice bath was used to maintain the temperature of the reaction. After 20 hr at room temperature, the organic layer was washed five times with aqueous KHSO₄ till the aqueous solution was at pH 1. The organic layer was then dried (MgSO₄) and concentrated to give a solid residue. Upon chromatographic purification via silica gel column of the solid residue, after trituration with pentane, a off-white solid (2.403 g, 28.6% yield, 97.0% HPLC purity) was provided as the desired product, m. p. 82-83 C.

Example 7 Preparation of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-chlorodifluoromethylsulfenyl-5-hydroxypyrazole

[0182] To the solution of 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-5-hydroxypyrazole (12.0 g, 37.3 mmol.) and pyridine (3.25 g, 41.0 mmol) in dichloromethane at −50 to −60 C was added chlorodifluoromethanesulfenyl chloride (8.1 g, 46.6 mmol). The resulting solution was gradually warmed up to room temperature. After 20 hr, the organic layer was washed five times with water. It was then washed with brine and dried (Na₂SO₄) to provide an oil. Upon chromatographic purification of the oil, a total of 11.6 g (26.4 mmol., 71% yield) of the desired product with 97% HPLC purity was isolated. F-NMR: −30.05 ppm (CClF₂), −63.80 ppm (ArCF₃).

Biological Example

[0183] The compounds 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluromethylthio-5-hydroxypyrazole, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfinyl-5-hydroxypyrazole and 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole are formulated as 30 mg/mL formulations in a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil. Using this formulation, mixed breed dogs and cats are treated at a rate of 10 mg of the compound per kg (mg/kg)of body weight of the dog and 20 mg/kg of the cat treated. The animals are fasted for at least 8 hours prior to treatment, fed half of the daily ration immediately prior to treatment, then allowed access to the remainder of the daily ration immediately following treatment.

[0184] All dogs are infested with cat fleas (Ctenocephalides felis) and with ticks (Rhipicephalus sanguineus) 1 day prior to administration of the compound. Cats are only infested with fleas. The initial flea and tick counts are performed 1 day after the administration of the compounds. At 7, 14, 21 and 28 days after treatment the dogs are re-infested with ticks and 8, 15, 22 and 29 days after treatment the dogs and cats are re-infested with fleas. At 1, 9, 16, 23 and 30 days after treatment the control of fleas and ticks in treated dogs and cats is determined versus a group of infested dogs and cats which receive a placebo consisting of a 1:1 volume/volume solution of dimethyl sulfoxide and corn oil. To determine the efficacies of the compounds, the arthropods are combed from the animals and counted.

[0185] Satisfactory results are obtained for many of the above-mentioned compounds in any of the three areas of evaluation without any significant side-effect for a period ranging from eight to thirty days: control of flea on dog, control of tick on dog, and control of flea on cat. They are: 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-trimethylacetoxypyrazole 3-10, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-ethoxypyrazole 3-1,1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-chlorodifluoromethylsulfenyl-5-hydroxypyrazole 1-9, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfenyl-5-hydroxypyrazole 1-1, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole 1-5, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfinyl-5-hydroxypyrazole 1-3, 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluormethylsulfonyl-5-N,N-dimethylcarbamyloxypyrazole 19-1. 

What is claimed is:
 1. A compound having the formula (II):

wherein: R₂₁ is cyano, C(═S)NH₂, C(═NOH)NH₂ or C(═NNH₂)NH₂; R₂₂ is S(O)_(m)R₂₃; R₂₃ is alkyl or haloalkyl; R₂₄ is OH, HC(O)O—, R₂₆C(O)O—, R₂₅OC(O)O—, R₂₅R₂₅N—C(O)—O— or R₂₅S(O)_(n)C(O)O—; R₂₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl or C₂-C₆ alkynyl; or two groups R₂₅ form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; X is selected from the group consisting of nitrogen and C—R₃₂; R₃₁ and R₃₂ are independently selected from the group consisting of halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂; R₃₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O)_(r)CF₃ and SF₅; m is selected from the group consisting of 0, 1 or 2; and r is selected from the group consisting of 0, 1 and 2; or a veterinarily acceptable salt thereof; provided that when R₂₁ is cyano, then R₂₄ is not R₂₅R₂₅—N—C(O)—O—, and further provided that the compound is other than 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylthio-5-hydroxypyrazole.
 2. A compound according to claim 1, wherein: R₂₁ is cyano; R₂₂ is S(O)_(m)R₂₃; R₂₃ is haloalkyl; R₂₄ is OH; X is nitrogen or C—R₃₂; R₃₁ and R₃₂ are independently selected from halogen; R₃₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O)_(r)CF₃, and —SF₅; and m and r are independently selected from the group consisting of 0, 1, and
 2. 3. A compound according to claim 2, wherein R₂₃ is CF₃.
 4. The compound according to claim 2, which is 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfinyl-5-hydroxypyrazole.
 5. The compound according to claim 2, which is 1-(2,6-dichloro-4-trifluoromethylphenyl)-3-cyano-4-trifluoromethylsulfonyl-5-hydroxypyrazole.
 6. A compound having the formula (I):

wherein: R₂₀₁ is cyano, C(O)alkyl, C(S)NH₂, C(NH)OR₂₀₃, C(NH)SR₂₀₃, alkyl, C(═NOH)NH₂, C(═NNH₂)NH₂, C(O)NH₂, C(O)NHR₂₀₆, C(O)NR₂₀₅R₂₀₆, haloalkyl or heterocyclyl selected from the group consisting of:

optionally substituted by R₂₀₃; R₂₀₂ is S(O)_(h)R₂₀₃, C₂-C₆ alkenyl, C₂-C₆ haloalkenyl, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl, C₂-C₆ alkynyl, nitro or imidazol-2-yl optionally substituted by alkyl, alkoxy, haloalkyl, halogen, cyano and/or nitro; R₂₀₃ is alkyl or haloalkyl; R₂₀₄ is —OH, R₂₀₅O—, HC(O)O—, R₂₀₅C(O)O—, R₂₀₅OC(O)O—, NH₂C(O)O—, R₂₀₅NHC(O)O—, R₂₀₅R₂₀₆NC(O)O—, R₂₀₅S(O)_(n)C(O)O—, R₂₀₆SO₂O—, aryl-SO₂O—, (C₄-C₇)-oxacycloalkyloxy, R₂₀₅R₂₀₆N—C(NR₂₀₅)—O—, R₂₀₅R₂₀₆N—C(NH)—O—, R₂₀₅NH—C(NR₂₀₅)—O—, R₂₀₅NH—C(NH)—O—, R₂₀₅N CH—O—, R₂₀₅N═C(R₂₀₆)—O—, R₂₀₅NH—C(S)—O— or R₂₀₅R₂₀₆N—C(S)—O—; R₂₀₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl or C₂-C₆ alkynyl; R₂₀₆ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted or hetarylalkyl optionally substituted; or R₂₀₅ and R₂₀₆ form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; X₁ is selected from the group consisting of nitrogen and C—R₂₁₂; R₂₁₁ and R₂₁₂ are independently selected from the group consisting of halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂; R₂₁₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅, or R₂₁₃ forms a ring with R₂₁₄; R₂₁₄ is hydrogen or together with R₂₁₃ forms a group OCF₂O, CF₂OCF₂, CF₂OCF₂O or CF₂CF₂O, which group forms together with the carbons to which it is attached a five to six membered ring; and h, k and n are independently selected from the group consisting of 0, 1, and 2; or a veterinarily acceptable salt thereof.
 7. A compound according to claim 6, wherein: R₂₀₁ is cyano, C(O)alkyl, C(S)NH₂, alkyl, C(═NOH)NH₂ or C(═NNH₂)NH₂; R₂₀₂ is S(O)_(h)R₂₀₃, C₂-C₃ alkenyl, C₂-C₃ haloalkenyl, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl or C₂-C₃ alkynyl; R₂₀₄ is —OH, R₂₀₅O—, HC(O)O—, R₂₀₅C(O)O—, R₂₀₅OC(O)O—, NH₂C(O)O—, R₂₀₅NHC(O)O—, R₂₀₅R₂₀₆NC(O)O— or R₂₀₅S(O)_(n)C(O)O—; R₂₀₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, or di(haloalkyl)aminoalkyl; R₂₀₆ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl or haloalkoxyalkyl; or R₂₀₅ and R₂₀₆ form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; R₂₁₁ and R₂₁₂ are independently selected from the group consisting of halogen, hydrogen, CN and NO₂; R₂₀₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅; and R₂₁₄ is hydrogen.
 8. A compound according to claim 6, wherein: R₂₀₁ is cyano; R₂₀₂ is S(O)_(h)R₂₀₃; R₂₀₃ is alkyl or haloalkyl; R₂04 is OH or R₂₀₅O; R₂₁₁ and R₂₁₂ are independently selected from the group consisting of halogen, hydrogen, CN and NO₂; and R₂₁₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅.
 9. A compound according to claim 6, having at least one feature selected from the group consisting of: R₂₀₁ is cyano; R₂₀₃ is halomethyl; R₂₁₁ and R₂₁₂ are independently halogen; X₁ is C—R₂₁₂; and R₂₁₃ is haloalkyl, haloalkoxy or —SF₅—.
 10. A compound according to claim 6, with the proviso that when R₂₀₁ is CN and R₂₀₂ is S(O)_(h)R₂₀₃, then R₂₀₄ is not R₂₀₅O or R₂₀₅R₂₀₆N—C(O)—O.
 11. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound of formula (II) as defined in claim 1, or a veterinarily acceptable salt thereof, and a veterinarily acceptable carrier therefor.
 12. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 2, and a veterinarily acceptable carrier therefor.
 13. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 3, and a veterinarily acceptable carrier therefor.
 14. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 4, and a veterinarily acceptable carrier therefor.
 15. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 5, and a veterinarily acceptable carrier therefor.
 16. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 6, and a veterinarily acceptable carrier therefor.
 17. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 7, and a veterinarily acceptable carrier therefor.
 18. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 8, and a veterinarily acceptable carrier therefor.
 19. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 9, and a veterinarily acceptable carrier therefor.
 20. A composition comprising a parasiticidally effective, substantially non-emetic amount of a compound as defined in claim 10, and a veterinarily acceptable carrier therefor.
 21. A method of controlling parasites in or on an animal in need of same comprising administering to said animal a parasiticidally effective, substantially non-emetic amount of a compound of formula (I):

wherein: R₂₀₁ is cyano, C(O)alkyl, C(S)NH₂, C(NH)OR₂₀₃, C(NH)SR₂₀₃, alkyl, C(═NOH)NH₂, C(═NNH₂)NH₂, C(O)NH₂, C(O)NHR₂₀₆, C(O)NR₂₀₅R₂₀₆, haloalkyl or heterocyclyl selected from the group consisting of:

optionally substituted by R₂₀₃; R₂₀₂ is S(O)_(h)R₂₀₃, C₂-C₆ alkenyl, C₂-C₆ haloalkenyl, cycloalkyl, halocycloalkyl, cycloalkyl-alkyl, C₂-C₆ alkynyl, nitro or imidazol-2-yl optionally substituted by alkyl, alkoxy, haloalkyl, halogen, cyano and/or nitro; R₂₀₃ is alkyl or haloalkyl; R₂₀₄ is —OH, R₂₀₅O—, HC(O)O—, R₂₀₅C(O)O—, R₂₀₅OC(O)O—, NH₂C(O)O—, R₂₀₅NHC(O)O—, R₂₀₅R₂₀₆NC(O)O—, R₂₀₅S(O)_(n)C(O)O—, R₂₀₆SO₂O—, aryl-SO₂O—, (C₄-C₇)-oxacycloalkyloxy, R₂₀₅R₂₀₆N—C(NR₂₀₅)—O—, R₂₀₅R₂₀₆N—C(NH)—O—, R₂₀₅NH—C(NR₂₀₅)—O—, R₂₀₅NH—C(NH)—O—, R₂₀₅N═CH—O—, R₂₀₅N═C(R₂₀₆)—O—, R₂₀₅NH—C(S)—O— or R₂₀₅R₂₀₆N—C(S)—O—; R₂₀₅ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, adamantyl, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, haloalkylaminoalkyl, di(haloalkyl)aminoalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted, hetarylalkyl optionally substituted, C₂-C₆ alkenyl or C₂-C₆ alkynyl; R₂₀₆ is alkyl, haloalkyl, cycloalkyl, halocycloalkyl, alkoxyalkyl, haloalkoxyalkyl, aryl optionally substituted, hetaryl optionally substituted, arylalkyl optionally substituted or hetarylalkyl optionally substituted; or R₂₀₅ and R₂₀₆ form together with the nitrogen to which they are attached a 3 to 7 membered ring which optionally has one or more additional heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur; X₁ is selected from the group consisting of nitrogen and C—R₂₁₂; R₂₁₁ and R₂₁₂ are independently selected from the group consisting of halogen, hydrogen, CN, C₁-C₃ alkyl and NO₂; R₂₁₃ is selected from the group consisting of halogen, haloalkyl, haloalkoxy, —S(O)_(k)CF₃, and —SF₅, or R₂₁₃ forms a ring with R₂₁₄; R₂₁₄ is hydrogen or together with R₂₁₃ forms a group OCF₂O, CF₂OCF₂, CF₂OCF₂O or CF₂CF₂O, which group forms together with the carbons to which it is attached a five to six membered ring; and h, k and n are independently selected from the group consisting of 0, 1, and 2; or a veterinarily acceptable salt thereof.
 22. A method according to claim 21, wherein the compound of formula (I) is administered in the form of a composition comprising a parasiticidally effective, substantially non-emetic amount of a compound of formula (I) or a veterinarily acceptable salt thereof and a veterinarily acceptable carrier therefor.
 23. A method according to claim 21, wherein the animal is a domestic animal.
 24. A method according to claim 23, wherein the domestic animal is a cat.
 25. A method according to claim 23, wherein the domestic animal is a dog.
 26. A method according to claim 21, wherein the compound of formula (I) or veterinarily acceptable salt thereof is administered orally to the animal in a dose of from 0.1 to 500 mg/kg.
 27. A method according to claim 26, wherein the dose administered is from 1 to 100 mg/kg.
 28. A method according to claim 27, wherein the dose administered is from 1 to 50 mg/kg.
 29. A method according to claim 28, wherein the dose administered is from 2 to 25 mg/kg.
 30. A method according to claim 29, wherein the dose administered is from 3 to 15 mg/kg. 